Compare LNTH & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | CZR |
|---|---|---|
| Founded | 1956 | 1937 |
| Country | United States | United States |
| Employees | N/A | 15500 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.0B |
| IPO Year | 2014 | 2015 |
| Metric | LNTH | CZR |
|---|---|---|
| Price | $100.93 | $29.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $87.00 | $31.92 |
| AVG Volume (30 Days) | 1.6M | ★ 3.5M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | $343,374,000.00 | ★ $1,473,504,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | $14.19 | $2.48 |
| P/E Ratio | $34.65 | ★ N/A |
| Revenue Growth | 3.62 | ★ 65.03 |
| 52 Week Low | $49.67 | $17.86 |
| 52 Week High | $111.86 | $30.88 |
| Indicator | LNTH | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 47.50 |
| Support Level | $100.51 | $29.52 |
| Resistance Level | $102.66 | $30.86 |
| Average True Range (ATR) | 0.53 | 0.11 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 50.86 | 34.55 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.